Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)’s earnings report is awaited on April, 1., as reported by Faxor. Analysts forecast 58.82 % diference or $-0.42 from the $-1.02 EPS from 2018. Last quarter $-0.66 earnings per share was reported. Analysts predicts -36.36 % EPS growth this quarter. TTNP is hitting $2 during the last trading session, after increased 11.73%.Currently Titan Pharmaceuticals, Inc. is downtrending after 70.03% change in last March 21, 2018. TTNP has 7,528 shares volume. TTNP underperformed by 74.40% the S&P500.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States.The company has $25.99 million market cap. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases.Last it reported negative earnings. The firm offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
For more Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) news published recently go to: Prnewswire.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “Titan Pharmaceuticals Partners With AllianceRx Walgreens Prime Specialty Pharmacy To Expand Patient Access To Probuphine® – PRNewswire” published on February 25, 2019, “Midday Gainers / Losers – Seeking Alpha” on February 25, 2019, “Mid-Day Market Update: Crude Oil Down 2.5%; Titan Pharmaceuticals Shares Spike Higher – Nasdaq” with a publish date: February 25, 2019, “Titan Pharmaceuticals teams up with AllianceRX Walgreens Prime; shares up 65% premarket – Seeking Alpha” and the last “28 Stocks Moving In Monday’s Pre-Market Session – Benzinga” with publication date: February 25, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.